ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 719,77
0,35%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Zevra Therapeutics Inc (ZVRA)

  7. Zevra Therapeutics Inc (ZVRA) Actualités

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
DateHeureSourceTitreSymboleSociété
16/05/202403h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
13/05/202422h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
09/05/202422h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
09/05/202413h30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor EventsNASDAQ:ZVRAZevra Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
01/05/202413h30GlobeNewswire Inc.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024NASDAQ:ZVRAZevra Therapeutics Inc
29/04/202413h30GlobeNewswire Inc.Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024NASDAQ:ZVRAZevra Therapeutics Inc
15/04/202423h01GlobeNewswire Inc.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
10/04/202413h30GlobeNewswire Inc.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202421h32GlobeNewswire Inc.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202412h42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ZVRAZevra Therapeutics Inc
26/03/202421h30GlobeNewswire Inc.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaNASDAQ:ZVRAZevra Therapeutics Inc
25/03/202421h30GlobeNewswire Inc.Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
18/03/202412h30GlobeNewswire Inc.Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024NASDAQ:ZVRAZevra Therapeutics Inc
04/03/202413h30GlobeNewswire Inc.Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
28/02/202413h30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
14/02/202422h51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ZVRAZevra Therapeutics Inc
06/02/202413h30GlobeNewswire Inc.Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
02/02/202413h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
23/01/202413h30GlobeNewswire Inc.Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of DirectorsNASDAQ:ZVRAZevra Therapeutics Inc
11/01/202422h50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:ZVRAZevra Therapeutics Inc
08/01/202413h30GlobeNewswire Inc.Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
04/01/202414h55GlobeNewswire Inc.Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical OfficerNASDAQ:ZVRAZevra Therapeutics Inc
27/12/202314h24Dow Jones NewsZevra Therapeutics Refiles Arimoclomol Application With FDANASDAQ:ZVRAZevra Therapeutics Inc
27/12/202313h30GlobeNewswire Inc.Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug AdministrationNASDAQ:ZVRAZevra Therapeutics Inc
20/11/202313h30GlobeNewswire Inc.Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease CompanyNASDAQ:ZVRAZevra Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial ResultsNASDAQ:ZVRAZevra Therapeutics Inc
31/10/202312h30GlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ETNASDAQ:ZVRAZevra Therapeutics Inc
30/10/202321h42Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ZVRAZevra Therapeutics Inc
19/10/202313h30GlobeNewswire Inc.Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout OctoberNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

Dernières Valeurs Consultées

COIN
UNRCGBP
BOV
CHVX34Q
Chevron
BIT
I09023
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés